Cargando…
Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
To elucidate the mechanism of glucose intolerance in patients with chronic liver disease(CLD), we measured the levels of plasma glucose, insulin and C-peptide during oral glucose tolerance test and urinary excretion of C-peptide per 24 hours during a weight maintenance diet in 20 patients with CLD w...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534913/ https://www.ncbi.nlm.nih.gov/pubmed/3154815 http://dx.doi.org/10.3904/kjim.1987.2.1.37 |
_version_ | 1782385526736683008 |
---|---|
author | Min, Yong Ki Suh, Kyo II Choi, Sang Jeon Lee, Hong Kyu Kim, Chung Yong Koh, Chang-Soon Min, Hun Ki |
author_facet | Min, Yong Ki Suh, Kyo II Choi, Sang Jeon Lee, Hong Kyu Kim, Chung Yong Koh, Chang-Soon Min, Hun Ki |
author_sort | Min, Yong Ki |
collection | PubMed |
description | To elucidate the mechanism of glucose intolerance in patients with chronic liver disease(CLD), we measured the levels of plasma glucose, insulin and C-peptide during oral glucose tolerance test and urinary excretion of C-peptide per 24 hours during a weight maintenance diet in 20 patients with CLD who had fasting plasma glucose(FBS) of less than 100 mg/dl. The patients with CLD who had normal FBS(FBS less than 100 mg/dl) were divided into two groups by the National Diabetes Data Group Criteria: one with abnormal glucose tolerance (abnormal GTT, Group 1) and the other with normal glucose tolerance (normal GTT. Group 2). Group 1 patients showed significantly higher plasma insulin (p<0.02 and p<0.01, respectively) and C-peptide concentrations (p<0.01) in the fasting state and 2 hours after a 75gram oral glucose loading (PP2) than group 2 patients. Urinary excretion of C-peptide per 24 hours was also higher in group 1 patients than in group 2 patients (p<0.01). Group 2 patients demonstrated similar plasma insulin, C-peptide and urinary excretion of C-peptide per 24 hours to normal subjects (p>0.05). These results suggest that patients with CLD who had normal FBS can be divided into two groups by oral glucose tolerance test(GTT) and those with abnormal GTT have hyperinsulinemia the mechanism of which is insulin hypersecretion from pancreatic B-cell. |
format | Online Article Text |
id | pubmed-4534913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1987 |
publisher | Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-45349132015-10-02 Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease Min, Yong Ki Suh, Kyo II Choi, Sang Jeon Lee, Hong Kyu Kim, Chung Yong Koh, Chang-Soon Min, Hun Ki Korean J Intern Med Original Article To elucidate the mechanism of glucose intolerance in patients with chronic liver disease(CLD), we measured the levels of plasma glucose, insulin and C-peptide during oral glucose tolerance test and urinary excretion of C-peptide per 24 hours during a weight maintenance diet in 20 patients with CLD who had fasting plasma glucose(FBS) of less than 100 mg/dl. The patients with CLD who had normal FBS(FBS less than 100 mg/dl) were divided into two groups by the National Diabetes Data Group Criteria: one with abnormal glucose tolerance (abnormal GTT, Group 1) and the other with normal glucose tolerance (normal GTT. Group 2). Group 1 patients showed significantly higher plasma insulin (p<0.02 and p<0.01, respectively) and C-peptide concentrations (p<0.01) in the fasting state and 2 hours after a 75gram oral glucose loading (PP2) than group 2 patients. Urinary excretion of C-peptide per 24 hours was also higher in group 1 patients than in group 2 patients (p<0.01). Group 2 patients demonstrated similar plasma insulin, C-peptide and urinary excretion of C-peptide per 24 hours to normal subjects (p>0.05). These results suggest that patients with CLD who had normal FBS can be divided into two groups by oral glucose tolerance test(GTT) and those with abnormal GTT have hyperinsulinemia the mechanism of which is insulin hypersecretion from pancreatic B-cell. Korean Association of Internal Medicine 1987-01 /pmc/articles/PMC4534913/ /pubmed/3154815 http://dx.doi.org/10.3904/kjim.1987.2.1.37 Text en Copyright © 1987 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Min, Yong Ki Suh, Kyo II Choi, Sang Jeon Lee, Hong Kyu Kim, Chung Yong Koh, Chang-Soon Min, Hun Ki Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease |
title | Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease |
title_full | Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease |
title_fullStr | Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease |
title_full_unstemmed | Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease |
title_short | Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease |
title_sort | glucose, insulin and c-peptide kinetics during an oral glucose tolerance test in patients with chronic liver disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534913/ https://www.ncbi.nlm.nih.gov/pubmed/3154815 http://dx.doi.org/10.3904/kjim.1987.2.1.37 |
work_keys_str_mv | AT minyongki glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease AT suhkyoii glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease AT choisangjeon glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease AT leehongkyu glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease AT kimchungyong glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease AT kohchangsoon glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease AT minhunki glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease |